TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models
| العنوان: | TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models |
|---|---|
| المؤلفون: | Yu Zhang, Li Ma, Shuguang Dong, Qiaoyan Ding, Shuman Wang, Qi Wu, Ping Ni, Hong Zhang, Yonggang Chen, Jinhu Wu, Xiong Wang |
| المصدر: | Endocrine-Related Cancer. 29:703-716 |
| بيانات النشر: | Bioscientifica, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Lipopolysaccharides, Cancer Research, Estradiol, Endocrinology, Diabetes and Metabolism, Estrogens, p38 Mitogen-Activated Protein Kinases, Prolactin, Mice, Inbred C57BL, Toll-Like Receptor 4, Mice, Endocrinology, Oncology, Animals, Humans, Estrogen Receptor beta, Pituitary Neoplasms, Prolactinoma |
| الوصف: | Prolactinomas have harmful effects on human health. Bromocriptine is the only commercially available drug in China, but about 25% of prolactinoma patients do not respond to it in clinic, its pathogenesis remains unknown. Thus, its pathogenesis needs to be determined to develop new therapeutic methods for prolactinomas. The expression of ERβ, TLR4, and prolactin (PRL) in the pituitary gland of C57BL/6 mice and human prolactinoma specimen was examined by immunofluorescence or immunohistochemistry. The role of TLR4 in prolactinoma was determined using estradiol-induced models of C57BL/6 wild-type and TLR4−/− mice. MMQ cells were treated with estradiol, fulvestrant, and lipopolysaccharide (LPS) or transfected with TLR4 siRNA to study the expression of ERβ, TLR4, and PRL in these cells. Furthermore, the interaction between ERβ and TLR4 was investigated by immunoprecipitation analysis. The expression of PRL and TLR4 was co-located and increased in the pituitary gland of mice and human prolactinoma specimen compared to that in the control specimen. Meanwhile, TLR4 knockout or treatment with the TLR4 inhibitor TAK242 not only significantly inhibited tumor overgrowth but also decreased the expression of PRL in estradiol-treated mice through p38 MAPK pathway regulation. However, MMQ treated with estradiol and LPS enhanced PRL expression than treated with estradiol or LPS alone. Finally, ERβ or TLR4 inhibition prevented the estradiol-induced PRL increase by regulating the TLR4/p38 MAPK pathway in vitro. Estradiol promoted prolactinoma development by activating the TLR4/p38 MAPK pathway through ERβ, and TLR4 is a potential therapeutic target for prolactinoma treatment. |
| تدمد: | 1479-6821 1351-0088 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95a72280fce26f4ddf3649c8548d2524 https://doi.org/10.1530/erc-22-0168 |
| رقم الأكسشن: | edsair.doi.dedup.....95a72280fce26f4ddf3649c8548d2524 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14796821 13510088 |
|---|